Glenmark Pharmaceuticals Inc., USA recalls Alyacen 7/7/7
- Published
- 24 Jun 2026
- Agency
- FDA
- Country
- United States
The hazard
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/0.035mg, 0.75mg/0.035mg, 1 mg/0.0.35mg, 3 Blister Cards each containing 28 tablets, 28 day regimen, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa 403 513, India, Manufactured for: Glenmark Pharmaceuticals Inc., Mahwah, NJ 07430, NDC 68462-556-29
- Brand / company
- Glenmark Pharmaceuticals Inc., USA
- Codes / lots
- Lot #: 20240411, Exp: 6/30/2026; 20250252, Exp: 3/31/2027
- Distribution
- USA Nationwide.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 24 Jun 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.